Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VXA-A1.1 Influenza Challenge Study
NCT02918006Phase 2Completed
- Sponsor
- Vaxart, Inc.
- Start
- Aug 2016
- Primary completion
- Aug 2017
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VXA-A1.1 in influenza (3 arms), sponsored by Vaxart, Inc. Primary endpoint: Number of Subjects With Influenza-like Clinical Illness and Laboratory Confirmed Infection Post Challenge With a Homologous A Strain Influenza Virus. Started Aug 2016; status: completed.
02
Drugs
VXA-A1.1
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02918006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02918006.